New research shows a breath test called an eNose might help doctors determine which mesothelioma patients are most likely to respond to immunotherapy. Immunotherapy is one of the most promising new approaches to malignant mesothelioma. But not every patient responds. A new Dutch study suggests that biomarkers in a patient’s exhaled breath may be indicators of immunotherapy response. The eNose breath test can identify those biomarkers quickly and easily. The technology might make it easier to decide on the best mesothelioma treatment. Immunotherapy for Malignant Mesothelioma Pleural mesothelioma is a rare but deadly cancer of the lung lining. Until last year, chemotherapy with Alimta (pemetrexed) was the only FDA-approved systemic treatment. In 2020, the FDA approved a combination of immunotherapy … Continue reading Breath Test Could Predict Mesothelioma Immunotherapy Response
A new report says there is much for the mesothelioma community to be excited about in the technology known as exhaled breath analysis. Several studies suggest the method is as accurate at identifying mesothelioma as some more invasive tests. Researchers at the University of Leuven in Belgium led the new study. They analyzed six other studies on exhaled breath analysis The goal was to see how accurate the method is for diagnosing mesothelioma and other asbestos diseases. The researchers conclude that things look good for exhaled breath analysis, but there is more to learn. Searching for Signs of Mesothelioma Pleural mesothelioma is an aggressive lung-related cancer caused by exposure to asbestos. It can take decades to develop, but once it … Continue reading Exhaled Breath Analysis: Is it the Future of Mesothelioma Diagnosis?